E-mail a Wiley Online Library Link

William R. Friedenberg, Montserrat Rue, Emily A. Blood, William S. Dalton, Chaim Shustik, Richard A. Larson, Pieter Sonneveld and Philip R. Greipp Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) Cancer 106

Version of Record online: 17 JAN 2006 | DOI: 10.1002/cncr.21666

VAD (vincristine, doxorubicin, and dexamethasone) with and without valspodar (PSC-833) was evaluated in patients with recurring or refractory multiple myeloma. There was no improvement in clinical outcome and there was excess toxicity in the valspodar-treated group compared with VAD alone.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field